RKIP Antibodies

Santa Cruz Biotechnology features a diverse variety of RKIP monoclonal antibodies for investigating Raf Kinase Inhibitor Protein (RKIP) in various biological processes. RKIP monoclonal antibodies are suitable for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RKIP is a critical regulator of several signaling pathways, including those involved in cell proliferation, apoptosis, and metastasis. As a modulator of the Raf-MEK-ERK pathway, RKIP plays a significant role in cancer biology, where altered expression can influence tumor progression and response to therapy. Research has shown that RKIP expression levels can serve as potential biomarkers for disease progression and treatment outcomes. Scientists worldwide utilize RKIP monoclonal antibodies to advance understanding of cellular signaling mechanisms. Ongoing studies continue to reveal new functions of RKIP in different physiological and pathological conditions. Current research focuses on exploring RKIP's potential as a therapeutic target in various diseases. Santa Cruz Biotechnology monoclonal antibodies support researchers in advancing scientific knowledge and developing innovative therapeutic strategies.